Atarim Launches Market-First Fully Embedded AI Creative Team
TimeRewards Integrates with Sage Intacct to Streamline Time Tracking and Financial Operations for Growing Businesses
ibex Bohol Awarded First-Ever TESDA Enterprise-Based Education and Training Accreditation in Region
Rigetti Supports NVIDIA NVQLink, NVIDIA’s New Open Platform for AI Supercomputer-Quantum Integration
Check Point Redefines AI Security for Enterprises with AI Cloud Protect Powered by NVIDIA BlueField
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (NASDAQ:…
Initiated preclinical animal studies for MN-166 as a treatment for chlorine gas-induced induced lung disease…
BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or…
The exclusively licensed platform has potential application for any tumor target Preclinical development to continue…
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology…
Clinical trial programs for vidutolimod (CMP-001) in melanoma and head and neck cancer indications ongoing…
AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…
PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults…
Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with…
WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or…
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused…
Total Revenue for Q2 2021 was approximately $0.8 million Cash as of June 30, 2021…
Expanded installed base and booked initial revenue for Proteograph Product Suite REDWOOD CITY, Calif., Aug….
Secured up to $100 million of additional development funding through a non-dilutive financing transaction with…
BURLINGAME, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq:…
Bottom Line: Q2 2021 Net Income of $141,000 versus Q2 2020 Net Loss of ($766,000) PORTLAND,…
Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trials Cash, cash…
Announced FDA clearance of Investigational New Drug application (IND) for lanraplenib (LANRA) for treatment of…
First patient dosed in Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive…
— Topline data in ANG-3777 Phase 3 study now expected to be announced in early…